A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer

NCT07214662 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

136

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: GDC-0587
DRUG: Giredestrant
DRUG: Omeprazole

Sponsor

Genentech, Inc.